
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. has demonstrated a positive trajectory with its flagship product, WAKIX, achieving net revenues of $201.3 million in 4Q24, reflecting a 20% year-over-year increase, indicative of strong market demand and effective adoption strategies. The company is projected to significantly increase WAKIX sales, with estimates growing from approximately $160 million in 2020 to over $700 million by 2024, driven by a robust prescriber penetration exceeding 50% among a targeted prescriber base. Additionally, the company's expansion into orphan drug candidates, including those in pipeline phases for conditions such as Prader-Willi Syndrome and Dravet Syndrome, positions Harmony favorably to drive future growth and enhance shareholder value.
Bears say
Harmony Biosciences Holdings Inc. faces significant financial challenges, as evidenced by the removal of potential revenues from its key product WAKIX in the idiopathic hypersomnia (IH) market, leading to a $5 reduction in the estimated value of the pitolisant pipeline. Additionally, there are substantial risks including potential competition from sodium oxybate, a decline in the acquisition of new patients for WAKIX, and the uncertain outcomes of ongoing clinical trials for multiple drug candidates in the pipeline. The cumulative effect of these factors has resulted in a downward revision of the company's price target, which reflects growing concerns about future revenue growth and market position.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares